CompletedPhase 3ACTRN12610000590066

CASCAID Study: Cytisine as a smoking cessation aid

A single-blind randomised controlled non-inferiority clinical trial to evaluate the efficacy and safety of cytisine compared to usual care (21mg, 14mg, or 7mg nicotine patch, 4mg or 2mg nicotine gum or 2mg or 1mg nicotine lozenge nicotine replacement therapy (NRT) plus behavioural support) as a treatment for people who wish to stop smoking


Sponsor

Health Research Council NZ

Enrollment

1,310 participants

Start Date

Mar 29, 2011

Study Type

Interventional

Conditions

Summary

Cytisine is a medicine, derived from the Golden Rain Tree that partially blocks the effects of nicotine on the brain. Cytisine has been used as a smoking cessation treatment in several European countries since the 1960s, is inexpensive compared to other cessation medications and has few known side effects. Despite its long history of use there are few studies looking at whether cytisine actually works. Results from trials that have been undertaken suggest that taking cytisine almost doubles the chances of successfully quitting smoking, compared to a placebo. However, these studies were not conducted using modern research standards so their positive findings may not be valid. We propose to investigate the effectiveness of cytisine as a quit smoking aid and whether it is safe and acceptable to smokers.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests cytisine, a plant-based medication, as an aid to help people quit smoking. It is open to adults aged 18 and older who want to stop smoking, have phone access, and are not already using other stop-smoking products or therapies.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

1. Tabex (Registered Trademark) oral tablet - 1.5 mg of cytisine per tablet (Sopharma) for 28 days. 2. Including 8 weeks of smoking cessation behavioural support supplied via Quitline New Zealand (

1. Tabex (Registered Trademark) oral tablet - 1.5 mg of cytisine per tablet (Sopharma) for 28 days. 2. Including 8 weeks of smoking cessation behavioural support supplied via Quitline New Zealand (NZ) (usually 3 telephone counselling calls over an 8 week period)


Locations(1)

National, New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000590066


Related Trials